This Is MS Multiple Sclerosis Knowledge & Support Community

Speaking at the 2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers in Indianapolis, Indiana, Mr Samuel F. Hunter, MD, PhD, president of the Advanced Neurosciences Institute in Franklin, Tennessee, gave a presentation on outcomes in patients with relapsing multiple sclerosis (MS) treated with Lemtrada (alemtuzumab)......... Read More - http://www.ms-uk.org/lemtrada

In CARE-MS I, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates; the difference observed in slowing disability progression did not reach statistical significance. In CARE-MS II, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates, and accumulation of disability was significantly slowed in patients given Lemtrada vs. interferon beta-1a.

Can someone explain to me the difference between "slowing disability progression" and "accumulation of disability"? How can one reach statistical significance and the other not?

I'm still trying to figure out why aubagio claims that begin 7% better than placebo is "significant".

CureOrBust wrote:

In CARE-MS I, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates; the difference observed in slowing disability progression did not reach statistical significance. In CARE-MS II, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates, and accumulation of disability was significantly slowed in patients given Lemtrada vs. interferon beta-1a.

Can someone explain to me the difference between "slowing disability progression" and "accumulation of disability"? How can one reach statistical significance and the other not?

They are discussing two different studies, CARE-MS I and CARE-MS II.

Ah, that learn me for skim reading.